Bio-Rad Laboratories Total Long Term Liabilities 2010-2024 | BIO

Bio-Rad Laboratories total long term liabilities for the quarter ending September 30, 2024 were $2.618B, a 10.4% decline year-over-year.

  • Bio-Rad Laboratories total long term liabilities for 2023 were $3.035B, a 8.52% decline from 2022.
  • Bio-Rad Laboratories total long term liabilities for 2022 were $3.318B, a 3.36% decline from 2021.
  • Bio-Rad Laboratories total long term liabilities for 2021 were $3.433B, a 39.5% increase from 2020.

Bio-Rad Laboratories Total Long Term Liabilities 2010-2024 | BIO

  • Bio-Rad Laboratories total long term liabilities for 2023 were $3.035B, a 8.52% decline from 2022.
  • Bio-Rad Laboratories total long term liabilities for 2022 were $3.318B, a 3.36% decline from 2021.
  • Bio-Rad Laboratories total long term liabilities for 2021 were $3.433B, a 39.5% increase from 2020.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$203.2B
Stryker (SYK)$148.2B
Boston Scientific (BSX)$133.1B
EssilorLuxottica (ESLOY)$113.5B
Medtronic (MDT)$109B
Haleon (HLN)$42.9B
Lonza Group Ag (LZAGY)$42.1B
GE HealthCare Technologies (GEHC)$37.7B
ResMed (RMD)$35B
Terumo (TRUMY)$29.2B
Koninklijke Philips (PHG)$24.4B
Zimmer Biomet Holdings (ZBH)$22.1B
Insulet (PODD)$18.4B
Baxter (BAX)$16.6B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$9.5B
Demant (WILYY)$8.3B
Lantheus Holdings (LNTH)$5.5B
TG Therapeutics (TGTX)$4.7B
Haemonetics (HAE)$4.3B
ICU Medical (ICUI)$4.2B
Prestige Consumer Healthcare (PBH)$4.1B
Perrigo (PRGO)$3.7B
Envista Holdings (NVST)$3.5B
Neogen (NEOG)$3.3B
Agios Pharmaceuticals (AGIO)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.8B
QuidelOrtho (QDEL)$2.6B
Warby Parker (WRBY)$2.3B